Диссертация (1154752), страница 25
Текст из файла (страница 25)
Aziz, L.C. Ming,M.M.Manan//FrontPharmacol.–2017.–Vol.8.–URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300992/pdf/fphar-0800030.pdf. – (accessed: 17.12.2016)164.Retrospective Analysis of Spontaneous Adverse Drug Reactions ReportsRelating to Paediatric Patients [Electronic resource] / R. Rosli, L.C. Ming, N.Abd Aziz N, M.M. Manan MM // PLoS One. – 2016. – Vol. 11, № 6. – URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889073/pdf/pone.0155385.pdf.– (accessed: 11.01.2017)144165.Riley, J.B.
Physicians' liability for off-label prescriptions [Text] / J.B.Riley, P.A. Basilius // Hematol Oncol News Issues. – 2007. – P. 24–27166.Risk factors associated with adverse drug reactions in hospitalisedchildren: international multicentre study [Text] / A.N. Rashed, I.C.Wong, N.Cranswick, S.
Tomlin, W. Rascher, A. Neubert // Eur J Clin Pharmacol. – 2012.– Vol. 68, № 5. – P. 801–810167.Safety and outcomes of test doses for the evaluation of adverse drugreactions: a 5-year retrospective review [Text] / M. Iammatteo, K.G.Blumenthal ,R. Saff [et al.] // J Allergy Clin Immunol Pract. – 2014. – Vol. 2, № 6. – P.768–774168.Saiyed, M.M. Is off-label use a risk factor for adverse drug reactions inpediatric patients? A prospective study in an Indian tertiary care hospital [Text] /М.M. Saiyed, T.
Lalwani, D. Rana // Int J Risk Saf Med. – 2015. – Vol. 27, № 1.– P. 45–53169.Shehadi, W.H. Adverse reactions to intravascularly administered contrastmedia. A comprehensive study based on a prospective survey [Text] / W.H.Shehadi // Am J Roentgenol Radium Ther Nucl Med. – 1975. – Vol. 124, № 1. –P. 145–152170.Spontaneous reporting of adverse drug events by Korean regionalpharmacovigilance centers [Text] / Y.S.
Shin, Y.W. Lee, Y.H. Choi, B. Park [etal.] // Pharmacoepidemiol Drug Saf. – 2009. – Vol. 18, № 10. – P. 910–915171.Srba, J. Adverse drug reactions: analysis of spontaneous reporting systemin Europe in 2007-2009 [Text] / J. Srba, V. Descikova, J. Vlcek // Eur J ClinPharmacol. – 2012. – Vol. 68, №7. – P. 1057–1063172.Study on off-label use of medicinal products in the European Union[Electronic resource] / M. Weda, J. Hoebert, M. Vervloet, C. Moltó [et al.] //EuropeanUnion.–2017.–URL:https://ec.europa.eu/health/sites/health/files/files/documents/2017_02_28_final_study_report_on_off-label_use_.pdf. – (accessed: 10.04.2017)145173.Suspected adverse drug reactions reported for children worldwide: anexploratory study using VigiBase [Text] / K.
Star, G.N. Norén, K. Nordin, I.R.Edwards // Drug Saf. – 2011. – Vol. 34, № 5. – P. 415–428.174.Ten Common Questions (and Their Answers) About Off-label Drug Use[Text] / C.M. Wittich, M. Christopher, C.M. Burkle, W.L. Lanier // Mayo ClinProc. – 2012. – Vol. 87, № 10. – P. 982–990175.The impact of unlicensed and off-label drug use on adverse drug reactionsin paediatric patients [Text] / A.
Neubert, H. Dormann, J.Weiss [et al.] // DrugSaf. – 2004. – Vol. 27, № 13. – P. 1059–1067176.The importance of monitoring adverse drug reactions in pediatric patients:the results of a national surveillance program in Italy [Electronic resource] / C.Carnovale, T. Brusadelli, G. Zuccotti [et al.] // Expert Opin Drug Saf. – 2014. –Suppl. 1. –URL:doi: 10.1517/14740338.2014.928692.
– (accessed:28.12.2016)177.The importance of pharmacovigilance [Electronic resource] // WorldHealthOrganization.–2002.–URL:http://whqlibdoc.who.int/hq/2002/a75646.pdf.– (accessed:20.02.2017)178.The mechanism of inhibition of beta–oxidation by aspirin metabolites inskin fibroblasts fron Reye s syndrome patients and control [Text] / J.F. Glasgow ,B. Middleton, R. Moore, A.
Gray, J. Hill // Biochim Biophys Acta. – 1999. –Vol. 1454, № 1. – P. 115–125179.The value of reporting therapeutic ineffectiveness as an adverse drugreaction [Text] / R.H. Meyboom, M. Lindquist, A.K. Flygare [et al.] // DrugSafety. – 2000. – Vol. 23, № 2. – P. 95–99180.The WHO Adverse Reaction Terminology – WHO-ART. Terminology forcoding clinical information in relation to drug therapy. WHO-ART guide. [Text]// The Uppsala Monitoring Centre.
– 2014181.Unlicensed and Off-Label Drug Use in Children Before and AfterPediatric Governmental Initiatives [Text] / J. Corny, D. Lebel, B. Bailey, J.F.Bussières // J Pediatr Pharmacol Ther. – 2015. – Vol. 20, №4. – P. 316–328146182.Unlicensed and off-label drug use in paediatrics in a mother-child tertiarycare hospital [Text] / J. Corny, B. Bailey, D. Lebel, J.F. Bussières // PaediatrChild Health. – 2016.
– Vol. 21, № 2. – P. 83–87183.Uppsala Monitoring Centre [Electronic resource]. – URL: http://www.whoumc.org .– (accessed: 20.02.2017)184.Use of off-label nephrology-related drugs in hospitalized pediatric patients:a retrospective study [Text] / M. Yasinta, R.C. Che, C.Y. Hu [et al.] // World JPediatr.
– 2016. – Vol. 12, № 2. – P. 236–242185.Wallerstedt, S.M. Rates of spontaneous reports of adverse drug reactionsfor drugs reported in children: a cross-sectional study with data from the Swedishadverse drug reaction database and the Swedish Prescribed Drug Register [Text]/ S.M. Wallerstedt, G. Brunlöf, A. Sundström // Drug Saf. – 2011. – Vol. 34, №8. – P. 669–682186.WHO pilot research project for international monitoring of adversereaction to drugs [Electronic resource] / World Health Assembly, 20 // WorldHealthOrganization.–1967.–URL:http://www.who.int/iris/handle/10665/89523.– (accessed: 20.02.2017)187.WHO Model Formulary for Children [Electronic resource] // World Health–Organization.–2010.URL:–http://www.who.int/selection_medicines/list/WMFc_2010.pdf.(accessed:13.05.2017)188.//WHO Model List of Essential Medicines for Children [Electronic resource]WorldHealthOrganization.–2013.–http://apps.who.int/iris/bitstream/10665/93143/1/EMLc_4_eng.pdf?ua=1.URL:–(accessed: 22.05.2017)189.Wiktorowicz, M.
Pharmacovigilance in Europe and North America:divergent approaches [Text] / M. Wiktorowicz, J. Lexchin, K. Moscou // Soc SciMed. – 2012. – Vol. 75, № 1. – P. 165–70147190.Wimmer, S. The Safety of Drug Therapy in Children [Text] / S. Wimmer,A. Neubert, W. Rascher // Dtsch Arztebl Int. – 2015. – Vol. 112, № 46. – P.781–787191.Yellow Card Scheme [Electronic resource] // Medicines and Healthcareproducts Regulatory Agency.
– URL: https://yellowcard.mhra.gov.uk/.–(accessed: 03.03.2017)192.Zingg, W. Antibiotic use in children - off-label use [Text] / W. Zingg, K.M.Posfay-Barbe // Curr Drug Targets. – 2012. – Vol. 13, № 7. – P. 885–892.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
